SG11202007288VA - Transforming growth factor beta-resistant natural killer cells - Google Patents

Transforming growth factor beta-resistant natural killer cells

Info

Publication number
SG11202007288VA
SG11202007288VA SG11202007288VA SG11202007288VA SG11202007288VA SG 11202007288V A SG11202007288V A SG 11202007288VA SG 11202007288V A SG11202007288V A SG 11202007288VA SG 11202007288V A SG11202007288V A SG 11202007288VA SG 11202007288V A SG11202007288V A SG 11202007288VA
Authority
SG
Singapore
Prior art keywords
growth factor
natural killer
transforming growth
killer cells
factor beta
Prior art date
Application number
SG11202007288VA
Other languages
English (en)
Inventor
Dean Anthony Lee
Jennifer Ann Foltz-Stringfellow
Jena Edwards-Moseman
Original Assignee
Res Institute At Nationwide Children’S Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Institute At Nationwide Children’S Hospital filed Critical Res Institute At Nationwide Children’S Hospital
Publication of SG11202007288VA publication Critical patent/SG11202007288VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4225—Growth factors
    • A61K40/4229—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202007288VA 2018-01-30 2019-01-29 Transforming growth factor beta-resistant natural killer cells SG11202007288VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862623682P 2018-01-30 2018-01-30
PCT/US2019/015617 WO2019152387A1 (en) 2018-01-30 2019-01-29 Transforming growth factor beta-resistant natural killer cells

Publications (1)

Publication Number Publication Date
SG11202007288VA true SG11202007288VA (en) 2020-08-28

Family

ID=67478491

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202007288VA SG11202007288VA (en) 2018-01-30 2019-01-29 Transforming growth factor beta-resistant natural killer cells

Country Status (12)

Country Link
US (1) US20200368281A1 (https=)
EP (1) EP3746118A4 (https=)
JP (2) JP7591406B2 (https=)
KR (2) KR20250093419A (https=)
CN (1) CN111818941A (https=)
AU (1) AU2019213678B2 (https=)
BR (1) BR112020015490A2 (https=)
CA (1) CA3090096A1 (https=)
IL (2) IL276374B2 (https=)
MX (1) MX2020008044A (https=)
SG (1) SG11202007288VA (https=)
WO (1) WO2019152387A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023517220A (ja) * 2020-03-11 2023-04-24 リサーチ インスティテュート アット ネイションワイド チルドレンズ ホスピタル 微生物感染症の治療のためのｎｋ細胞およびそれらの使用
AU2021263579A1 (en) * 2020-04-30 2022-12-01 Research Institute At Nationwide Children's Hospital Overcoming immune suppression with TGF-β resistant NK cells
KR20250154429A (ko) * 2023-03-02 2025-10-28 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 암 면역요법을 위한 형질전환 성장인자-베타 슈퍼패밀리가 각인된 자연살해세포

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2058388A1 (en) * 2007-10-05 2009-05-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Non-conventional NKT cells for use in cancer therapy
WO2015103793A1 (zh) * 2014-01-13 2015-07-16 深圳市汉科生物工程有限公司 用带有活性因子的细胞空壳作为淋巴细胞体外培养增效剂的制备及其应用方法
EP3223856B1 (en) 2014-10-27 2025-09-24 University of Central Florida Research Foundation, Inc. Methods and compositions for natural killer cells
KR20180040706A (ko) * 2015-09-01 2018-04-20 인네이트 튜머 이뮤니티, 인코포레이티드 면역억제 시토카인에 대해 증가된 면역 또는 저항성을 갖는 면역 세포 및 그의 용도
WO2017048809A1 (en) * 2015-09-14 2017-03-23 Regents Of The University Of Minnesota Nk cells exhibiting an adaptive phenotype and methods for preparing and for using

Also Published As

Publication number Publication date
AU2019213678A1 (en) 2020-09-03
AU2019213678B2 (en) 2025-06-26
JP7591406B2 (ja) 2024-11-28
EP3746118A4 (en) 2021-11-24
US20200368281A1 (en) 2020-11-26
KR20250093419A (ko) 2025-06-24
IL309656A (en) 2024-02-01
EP3746118A1 (en) 2020-12-09
IL276374B1 (en) 2024-01-01
IL276374A (en) 2020-09-30
RU2020127722A (ru) 2022-02-28
MX2020008044A (es) 2020-12-10
KR20200118449A (ko) 2020-10-15
IL276374B2 (en) 2024-05-01
JP2025026937A (ja) 2025-02-26
CA3090096A1 (en) 2019-08-08
CN111818941A (zh) 2020-10-23
KR102822300B1 (ko) 2025-06-17
WO2019152387A1 (en) 2019-08-08
BR112020015490A2 (pt) 2021-03-23
JP2021512164A (ja) 2021-05-13

Similar Documents

Publication Publication Date Title
IL285543A (en) Modified natural killer (nk) cells for immunotherapy
EP3240552A4 (en) Natural killer cells and uses thereof
EP3223856A4 (en) Methods and compositions for natural killer cells
IL277467A (en) A method for producing natural killer cells
SG10201912576PA (en) Natural killer cells and ilc3 cells and uses thereof
EP3633029A4 (en) METHOD OF DEVELOPING A NATURAL KILLER CELL USING A T-CELL
GB201810486D0 (en) Natural killer cells
IL275780A (en) Ear formulations of growth factor
EP3686274A4 (en) METHOD OF MANUFACTURING A NATURAL KILLER CELL AND USE THEREOF
GB201704953D0 (en) Natural killer cells
EP3296620A4 (en) PLANT GROWTH LAMP
IL276374A (en) Natural killer cells are resistant to transforming growth factor beta
EP3524054A4 (en) PLANT GROWTH REGULATOR
IL268129A (en) Preparations and methods for controlling the activation and function of natural killer cells (NK cells)
GB201703476D0 (en) Natural killer cells
EP4083186A4 (en) Cell growth regulator
HK40032882A (en) Transforming growth factor beta-resistant natural killer cells
GB202102206D0 (en) Plant growth chamber
HK40073829A (en) Sirpalpha-silenced natural killer (nk) cells
HK40008589A (en) Genetically modified natural killer cells
HK40065188A (en) Switchable chimeric antigen receptor-engineered human natural killer cells
GB201817457D0 (en) Interfoliate lighting and root growth enhancement
HK40040241A (en) Methods of making natural killer cells and uses thereof
HK40056311A (zh) 人造骨膜
GB201918111D0 (en) Sun tree